Ascendis Pharma (ASND) PT Raised to $163 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ASND Hot Sheet
Price: $243.37 +0.16%
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
23 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Citi analyst David Lebowitz raised the price target on Ascendis Pharma (NASDAQ: ASND) to $163.00 (from $157.00) while maintaining a Buy rating.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Lockheed Martin (LMT) PT Raised to $692 at UBS
- CoreWeave (CRWV) PT Lowered to $105 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
